AR022116A1 - Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa - Google Patents
Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfaInfo
- Publication number
- AR022116A1 AR022116A1 ARP990106463A ARP990106463A AR022116A1 AR 022116 A1 AR022116 A1 AR 022116A1 AR P990106463 A ARP990106463 A AR P990106463A AR P990106463 A ARP990106463 A AR P990106463A AR 022116 A1 AR022116 A1 AR 022116A1
- Authority
- AR
- Argentina
- Prior art keywords
- hcv
- effective amount
- interferon alfa
- ribavirin
- weeks
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se revela el uso de ribavirina e interferon alfa para la manufactura de composiciones farmacéuticas para tratar un paciente con infeccion cronica dehepatitis C, por ejemplo un paciente que tiene el genotipo 1, 2 o 3 de VHC, para erradicar el ARN delVHC detectable, mediante un método que comprende laadministracion de una cantidad efectiva de ribavirina en asociacion con una cantidad efectiva de interferon alfa, que se caracteriza porque el tratamiento delos pacientes que tienen infeccionescroni cas de hepatitis C se efectua en dos períodos de tratamiento; (a) un primer período de tratamiento de al menos 20 a30 semanas, en el cual se administran una cantidad terapéuticamente efectiva de ribavirina y una cantidad dosificante deinduccion tera péuticamente efectiva deinterferon alfa, suficiente al menos para disminuir sustancialmente, y preferentemente para erradicar el ARN del VHC detectable; y b) un segundo período detratamiento de al menos de 20 a 30 semanas, donde unacantidad terapéut icamente efectiva de ribavirina y una cantidad terapéuticamente efectiva de interferonalfa se administran en forma suficiente para mantener el ARN del VHC no detectable, durante al menos de 20 a 30 semanas luego de finalizar elprimer períodode tra tamiento y para mantener el ARN del VHC no detectable durante al menos 24 semanas, luego de finalizar el segundo período de tratamiento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21587598A | 1998-12-18 | 1998-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR022116A1 true AR022116A1 (es) | 2002-09-04 |
Family
ID=22804763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106463A AR022116A1 (es) | 1998-12-18 | 1999-12-16 | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR022116A1 (es) |
| AU (1) | AU2156900A (es) |
| PE (1) | PE20001386A1 (es) |
| WO (1) | WO2000037097A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
| JP4849622B2 (ja) | 2004-08-11 | 2012-01-11 | 中外製薬株式会社 | Ｈｃｖ感染症を治療または予防するための薬剤 |
| US7723310B2 (en) | 2004-10-18 | 2010-05-25 | Three Rivers Pharmaceuticals, Llc | Large dose ribavirin formulations |
| CN101489580A (zh) * | 2006-05-16 | 2009-07-22 | 财团法人东京都医学研究机构 | 治疗或预防hcv感染症的药物组合物 |
| AU2008231705A1 (en) * | 2007-03-27 | 2008-10-02 | 4Sc Ag | Pharmaceutical composition comprising a cytokine |
| EP1977759A1 (en) * | 2007-03-27 | 2008-10-08 | 4Sc Ag | Pharmaceutical composition comprising a cytokine |
| US20110270212A1 (en) * | 2007-10-05 | 2011-11-03 | Medtronic, Inc. | Pharmacokinetic control for optimized interferon delivery |
| JPWO2010061881A1 (ja) | 2008-11-26 | 2012-04-26 | 中外製薬株式会社 | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 |
| UY34402A (es) | 2011-10-21 | 2013-05-31 | Abbvie Inc | Métodos para el tratamiento de hcv |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| DE69810822T2 (de) * | 1997-09-21 | 2003-11-20 | Schering Corp | Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infection |
-
1999
- 1999-12-16 AU AU21569/00A patent/AU2156900A/en not_active Abandoned
- 1999-12-16 AR ARP990106463A patent/AR022116A1/es unknown
- 1999-12-16 WO PCT/US1999/027934 patent/WO2000037097A1/en active Application Filing
- 1999-12-17 PE PE1999001294A patent/PE20001386A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000037097A1 (en) | 2000-06-29 |
| AU2156900A (en) | 2000-07-12 |
| PE20001386A1 (es) | 2000-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
| AR019551A1 (es) | Uso de la ribavirina en combinacion con el interferon alfa para la fabricacion de un medicamento para la terapia de combinacion para erradicar hcv-rna detectable en pacientes no afectados a tratamiento antiviral que tienen infeccion de hepatitis c cronica | |
| HUP0003131A2 (hu) | Polietilénglikol/alfa-interferon konjugátumok fertőzés kezelésére | |
| WO2006130553A3 (en) | Hcv protease inhibitors | |
| CA2245938A1 (en) | Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| MA27292A1 (fr) | Procedes et compositions pour le traitement du virus de l'hepatite c | |
| WO2004002999A8 (en) | Modified 2' and 3' -nucleoside produgs for treating flaviridae infections | |
| BR9911076A (pt) | Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica | |
| AR021226A1 (es) | Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica | |
| AR022116A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa | |
| AR023541A1 (es) | Terapia de combinacion para vhc | |
| JP2017514834A5 (es) | ||
| DE60125377D1 (de) | Behandlung von hepatitis c mit thymosin, interferon und ribavirin | |
| TH53874A3 (th) | การบำบัดรักษา hcv แบบผสมผสานโดยการเหนี่ยวนำด้วยไรบาไวรินและอินเทอฟีรอนอัลฟาชนิดเพกิเลเตด | |
| ECSP993178A (es) | Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica | |
| TH33755A (th) | การรักษาร่วมเพื่อขจัด hcv-rna ที่ตรวจหาได้ในผู้ป่วยที่ติดเชื้อตับอักเสบ c เรื้อรัง | |
| DE60121449D1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon | |
| TH87484A (th) | Peg-ifn อัลฟา และริบาวิรินสำหรับรักษา hbv | |
| TH87484B (th) | Peg-ifn อัลฟา และริบาวิรินสำหรับรักษา hbv | |
| TH46769A (th) | การรักษาร่วมของ hcv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |